FDA's Orphan Drugs Program
Development of drugs for rare diseasesIncentives for Rare Disease Drug Development
The FDA’s Orphan Drug Program was established to encourage the development of drugs for rare diseases that affect fewer than 200,000 people in the U.S.
Because these diseases often lack market incentives due to small patient populations, the FDA offers benefits and protections to make developing these therapies more feasible for pharmaceutical companies.
By offering incentives such as market exclusivity for seven years, tax credits for clinical trials, and waived user fees, the program helps mitigate the financial risks for companies developing treatments for these conditions. Additionally, the program provides guidance and grants to support research and development efforts.
Since its inception in 1983, the program has led to the approval of over 1,100 orphan drugs, significantly improving treatment options for patients with rare diseases and conditions that previously lacked effective therapies.
Key Program Goals
- Stimulate research and development of drugs for rare diseases
- Ensure patients with rare conditions have access to safe and effective treatments
- Reduce the economic and regulatory barriers that discourage investment
What Qualifies a Drug for Orphan Status?
To qualify:
- The drug must treat, diagnose, or prevent a disease or condition affecting fewer than 200,000 people in the U.S., or
- If the population is larger, the sponsor must show there is no reasonable expectation of recovering development costs through U.S. sales.
Benefits of Orphan Drug Designation
When a product is granted orphan drug status, the sponsor receives several incentives:
| Benefit | Description |
| 7 Years of Market Exclusivity | After approval, the FDA will not approve a similar drug for the same indication |
| Tax Credits | Up to 25% of qualified clinical trial costs |
| Waived User Fees | FDA application and annual product fees may be waived |
| Assistance from FDA | Access to the Orphan Products Grants Program and guidance on study design |
| Eligibility for Grants | Competitive grant funding for clinical trials through the Office of Orphan Products Development (OOPD) |
Process Overview
- Sponsor applies for Orphan Drug Designation before submitting an NDA/BLA
- FDA reviews the application and grants designation if criteria are met
- After successful clinical trials, sponsor submits a marketing application
- If approved, the 7-year exclusivity and other incentives apply
Impact of the Program
- Over 1,100 orphan drugs have been approved since 1983
- Conditions treated range from rare cancers to genetic disorders, autoimmune diseases, and metabolic syndromes
- Has dramatically increased investment in previously neglected diseases
Examples of Orphan Drug Approvals
- Spinraza (nusinersen) – for spinal muscular atrophy
- Luxturna (voretigene neparvovec) – for inherited retinal dystrophy
- Zolgensma (onasemnogene abeparvovec) – gene therapy for SMA
- Lynparza (olaparib) – for BRCA-mutated ovarian cancer
- Lynozyfic (linvoseltamab-gcpt) – for relapsed/refractory multiple myeloma (recent)
Summary
| Feature | Orphan Drug Program |
| Target Diseases | Rare (≤200,000 U.S. patients) |
| Lead FDA Office | Office of Orphan Products Development (OOPD) |
| Key Benefits | Market exclusivity, tax credits, fee waivers |
| Approval Path | NDA/BLA after orphan designation |
| Major Goal |
Encourage R&D for underserved patient populations |
Read more about the program.
Read about the Orphan Drugs Program on the FDA website.
Implications of the New Federal Vaccine Schedule for Children
The New Federal Vaccine Schedule for Children: What Changed and What Are the Implications?Authors: Jennifer Kates and Josh Michaud, KFF This story was originally published by KFF.As widely expected, and following a recent Presidential memorandum, the Department of...
When Generic Drugs Are Not Equivalent
Fighting for BreathLung transplant patient Hannah Goetz’s life depended on the generic version of a critical drug. It was supposed to be equivalent to the brand-name medication — but the FDA doesn’t always ensure that’s the case.by Megan Rose and Debbie Cenziper,...
Proposed Bill Would Increase Drug Labeling Transparency
Proposed Legislation would Require Generic Drug Labels to Bear Manufacturer, Location, and Key Suppliers ProPublica's RX Inspector tool provides manufacturer location and inspection information for 40k generic drug manufacturersby by Debbie Cenziper, ProPublica,...